Haleon plc filings document foreign private issuer disclosures for a global consumer health company whose American depositary shares trade under HLN. Form 6-K reports cover current information such as trading statements, ordinary-share repurchases for cancellation, total voting rights and capital, and annual general meeting poll results.
The filing record also includes debt-market disclosures, including listing particulars for the Euro Medium Term Note programme of Haleon UK Capital plc and Haleon Netherlands Capital B.V. guaranteed by Haleon. Governance and capital-structure disclosures address directors' remuneration, board elections, dividend approvals, special resolutions, ordinary shares, treasury shares, voting rights and shareholder notification thresholds.
Haleon plc (HLN), through subsidiary Haleon US Capital LLC, is offering an aggregate $2.0 billion of senior unsecured notes under its automatic shelf registration. The Issuer will sell $600 million 4.625% notes due 2029, $600 million 4.875% notes due 2031 and $800 million 5.375% notes due 2036, all fully and unconditionally guaranteed by Haleon plc.
The notes price slightly below par, generating series net proceeds of $596.6 million (2029), $595.3 million (2031) and $789.8 million (2036), for estimated total net proceeds of about $1.98 billion before expenses. Haleon expects to use the proceeds, together with cash on hand if needed, to fund a Concurrent Tender Offer for any and all of its 3.375% notes due March 2027, of which $1.99935 billion was outstanding, and for general Group purposes. The notes are senior unsecured, rank pari passu with other senior unsecured debt, have make-whole call provisions prior to their respective Par Call Dates and are expected to be listed on the NYSE, although listing and secondary-market liquidity are not assured.
Haleon plc reports that its wholly owned subsidiary, Haleon Capital LLC, has launched and priced a $2 billion SEC‑registered, fixed‑rate USD bond offering across three senior tranches, scheduled to settle on 21 August 2026. The tranches comprise $600,000,000 notes due 2029 with a 4.625% coupon, $600,000,000 notes due 2031 with a 4.875% coupon, and $800,000,000 notes due 2036 with a 5.375% coupon. Principal and interest on all notes are fully and unconditionally guaranteed by Haleon plc.
The company expects to use the net proceeds, together with cash on hand if required, to repurchase in whole or in part $1,999,350,000 of its outstanding 3.375% Fixed Rate Senior Notes due March 2027 via a concurrent tender offer announced on 11 August 2026, and for general corporate purposes. Barclays, BofA Securities, Deutsche Bank Securities, Goldman Sachs and Mizuho served as joint book‑running managers. The announcement includes standard securities law legends and a cautionary note on forward‑looking statements.
Haleon plc reports that it has issued an exhibit dated 11 August 2026 describing a cash tender offer for its outstanding 2027 3.375% Fixed Rate Notes. The filing identifies the company as a foreign private issuer and provides notice of this debt-related transaction to U.S. investors.
Haleon plc has launched a cash tender offer for its outstanding 2027 3.375% Fixed Rate Notes. The company states that this tender offer, together with a planned issue of new bonds, is in line with its previously stated capital allocation priorities and is expected to help proactively manage and optimise its debt portfolio.
The detailed terms of the tender offer are provided in a separate announcement available via the London Stock Exchange and on Haleon’s investor website, and have also been submitted to the UK Financial Conduct Authority’s National Storage Mechanism.
Haleon US Capital LLC plans to issue three series of unsubordinated, unsecured senior fixed rate notes, fully and unconditionally guaranteed by Haleon plc. The notes rank pari passu with the issuers’ other unsubordinated, unsecured obligations, are issued in $1,000 denominations, and may be optionally redeemed at a make-whole Treasury Rate-based price before specified par call dates, or at par thereafter, plus accrued interest.
The company has launched a Concurrent Tender Offer to purchase for cash any and all of its $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027, with expiration scheduled for August 18, 2026 and anticipated settlement on August 21, 2026, subject to conditions including settlement of this new offering. Net proceeds from the new notes, together with cash on hand if needed, are intended to fund that tender and for general purposes of the Haleon group. As of June 30, 2026, total equity was £16,440 million, total borrowings £8,252 million, and total capitalization £24,692 million. Application will be made to list the new notes on the NYSE.
Haleon plc filed a post-effective amendment to its Form F-3 automatic shelf registration to correct the EDGAR header and formally add CIK codes for finance subsidiaries Haleon US Capital LLC and Haleon UK Capital plc as co-registrants, ensuring their securities are also registered. Under this shelf, the U.S. and U.K. Issuers may offer from time to time guaranteed debt securities fully and unconditionally guaranteed by Haleon plc, and Haleon plc may offer ordinary shares directly or as American depositary shares, each ADS representing two ordinary shares. The document outlines extensive risk factors covering competitive markets, leverage, international operations, exchange-rate exposure, and structural subordination of the guarantees to subsidiary liabilities. Haleon notes it is a consumer health company with around 24,500 employees and that net proceeds from offerings will be used for general Group purposes and other specific purposes identified in future prospectus supplements.
Haleon plc reports its share capital and voting structure as at 31 July 2026. The company has 8,820,906,422 ordinary shares of £0.01 each issued, of which 11,879,800 are held as treasury shares. This results in 8,809,026,622 ordinary shares with voting rights.
This voting-share figure is the denominator shareholders and others with notification obligations should use to determine whether they must notify their interest in Haleon under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon plc submitted an amended Form 6-K/A to update the reference to its latest shelf registration statement on Form F-3 filed on 29 July 2026. The amendment also confirms that the 30 July 2026 half year results are incorporated by reference into the Form F-3 (No. 333-297789) and the Form S-8 (No. 333-267647).
Haleon plc announced that its 2026 half year results statement for the year ending 31 December 2026 is now available on its investor website and through the UK Financial Conduct Authority’s National Storage Mechanism.
The Board declared an H1 2026 interim dividend of 2.4 pence per ordinary share, a 9% increase on the 2025 interim dividend and in line with the policy of paying about one third of the prior full-year dividend at the interim stage. The dividend is expected to be paid on 17 September 2026 to holders of ordinary shares and ADS on the register as of 14 August 2026, with ex-dividend dates of 13 August 2026 for ordinary shares and 14 August 2026 for ADS. A Dividend Reinvestment Programme is available with an election deadline of 28 August 2026. Management will provide a recorded results presentation and a Q&A session for analysts and shareholders on 30 July 2026.
Haleon plc reported H1 2026 revenue of £5,602m, up 2.2% on a reported basis and 2.6% organically. Reported gross margin rose to 65.9%, while adjusted gross margin reached 66.5%. Adjusted operating profit increased to £1,364m, with margin expanding to 24.3%, although reported operating profit declined 2.6% to £1,172m due mainly to restructuring costs linked to an operating model change.
Reported diluted EPS fell 4.5% to 8.5p, but adjusted diluted EPS rose 12.0% to 10.3p, helped by higher adjusted profit and a smaller share count. Net cash from operating activities was £1,044m and free cash flow £769m. Net debt stood at £7.5bn (2.5x net debt/adjusted EBITDA) after repaying an €850m bond, and £457m of a £500m 2026 share buyback had been completed. An interim dividend of 2.4p per share, 9% above 2025, was declared.
Operationally, 73% of the business gained or maintained market share, with strong growth in Oral Health and Pain Relief partly offset by a decline in Respiratory Health following a weak cold and flu season. Guidance for 2026 is unchanged, with expected organic revenue growth of 3–5% and high single-digit adjusted operating profit growth at constant currency, supported by ongoing productivity programmes and a medium-term goal of 50–80bps annual adjusted gross margin expansion.